Related Experiment Video
Updated: May 2, 2026
04:22
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
1.4K
Erectile dysfunction in patients with chronic hepatitis C virus infection
Shereen Shoukry Hunter1, Amr Gadallah2, Maan Khalaf Azawi2
1Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Summary
Approximately 30% of men with chronic Hepatitis C virus (HCV) infection experience erectile dysfunction (ED). ED prevalence and severity significantly increase with liver disease progression in HCV patients.
Area of Science:
- Hepatology
- Urology
- Public Health
Background:
- Chronic Hepatitis C virus (HCV) infection is a global health concern, particularly prevalent in Egypt.
- Emerging evidence suggests a link between chronic HCV infection and erectile dysfunction (ED) in men.
Purpose of the Study:
- To determine the prevalence of ED among male patients diagnosed with chronic HCV infection.
- To investigate the relationship between ED and the severity of liver disease in HCV patients.
Main Methods:
- A cohort of 150 male patients with chronic HCV infection was studied.
- Erectile dysfunction was assessed using the validated International Index of Erectile Function (IIEF-5).
- Liver cirrhosis severity was evaluated using the Child-Pugh score.
Main Results:
- The overall prevalence of ED was 29.3% among patients with chronic HCV infection.
- ED was significantly more prevalent in patients with liver cirrhosis compared to those with chronic hepatitis (p<0.001).
- A strong correlation was observed between ED severity and liver disease severity, with lower serum albumin and higher bilirubin levels associated with worse ED.
Conclusions:
- Chronic HCV infection is associated with a substantial prevalence of ED, nearing 30%.
- The severity of liver disease, particularly liver cirrhosis, significantly impacts ED in HCV patients.
- HCV infection should be considered in the differential diagnosis of ED, especially in high-prevalence regions like Egypt.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
01:25Hepatitis
86
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
823
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
823
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
01:23Cirrhosis I: Introduction
28
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28